However, in recent years, China has surpassed Europe in the number of new global drug approvals, and it is edging closer to the US.

VANCOUVER, British Columbia and BOSTON, Jan.

WALTHAM, Mass.

Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.

PALO ALTO, Calif.

GAITHERSBURG, Md.

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 WATERTOWN, Mass.

(RTTNews) - HUTCHMED (China) Ltd (HCM, HCM.